Kiniksa Pharmaceuticals International (KNSA) Other Operating Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Other Operating Expenses for 7 consecutive years, with $111.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 57.19% year-over-year to $111.6 million; the trailing twelve-month figure through Jun 2026 stood at $382.6 million (up 54.14% YoY), and the FY2025 full-year result was $307.2 million, up 62.36% from the prior year.
• Other Operating Expenses rose to $111.6 million in Q2 2026 per KNSA's latest filing, from $96.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $111.6 million in Q2 2026 and bottomed at $8.7 million in Q2 2022.
• Historically, Other Operating Expenses has averaged $46.7 million across 5 years, with a median of $36.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Other Operating Expenses surged 317.78% in 2022, then climbed 22.86% in 2023.
• Over 5 years, Other Operating Expenses stood at $14.2 million in 2022, then jumped by 86.36% to $26.5 million in 2023, then jumped by 149.16% to $66.1 million in 2024, then surged by 37.66% to $91.0 million in 2025, then advanced by 22.72% to $111.6 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $111.6 million, $96.4 million, and $91.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.